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cious in Pts with NYHA class IV HF due to systolic dysfunction. Although these results 
must be treated with caution due to the small number of Pts studied, lack of effective 
therapies and the high risk of NYHA class IV HF suggests strong consideration for 
digoxin therapy in this population. 
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1085-80 The Value of Dobutamine Stress Echo in Predicting 
Improvement in Left Ventricular Function in Patients 
With lschemic and Nonischemic Cardiomyopathy After 
One Year of Beta-Blocker Therapy 
Frank F. Seahatol. Dipan Shah, Silvia DiLuzio. David Belle, Mary1 R. Johnson, William G. 
Cotts, Jenny A. O’Donohue, Robert 0. Bonow, Mihai Gheorghiade, Vera H. Rigolin, 
Northwestern University, Chicago, IL 
Background: Beta-blockers reduce morbidity and mortality in chronic heart failure. How- 
war, the value of dobutamine stress echo (DSE) in predicting long-term global and seg- 
mental improvement in LV function in ischemic (IS) vs nonischemlc (NI) cardiomyopathy 
is not well defined. 
Methods: We studied 32 heart failure patients, 18 IS and 14 NI with LVEF< 35%. All 
were on stable doses of ACE-inhibitors. DSE was obtained prior to initiation of beta- 
blockers to define contractile reserve (CR). 2D echoes were bbtainad at baseline and 
after 12 months of carvedilol fw29. mean dose 47.0 +19.0 mold). metoorolol XL ln=2. 
_ I .  
mean dose 62.5 mg/d) or atenolol @=I, 12.5 mg/d). The left ventricle was divided into 16 
segments using the traditional ASE classification scheme. Contractility of each segment 
was assessed and an echo score (ES) was given. Each segment was classified as CR 
positive (+) or negative (-) based on presence or absence of improvement in ES 11 with 
low dose dobutamine (SmcgikgRnin) compared to baseline. The A EF was calculated as 
the difference in EF between baseline and 12 months. 
Results: See Fig. 
Conclusion: After 1 year of beta-blockers, EF and ES improve in both IS and NI patients 
irrespective of contractile reserve status. However, the magnitude of improvement IS 
greatest in NI patients with CR. 
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1085-81 Favorable Effects of Digoxin on Mortality and Morbidity 
in Patients With Class IV Congestive Heart Failure Due 
to Systolic Dysfunction: Retrospective Analysis of the 
DIG Study 
Kirkwood F. Adams, Jr., J. Herbert Patterson, Wendy A. Gattis, Christopher M. 
O’Connor. Todd A. Schwartz. Mihai Gheorahiade. Universitv of North Carolina - Chaoel _ 
Hill, Chapel Hill, NC 
Backgound: Previous small studies have suggested that digoxin exerts beneficial effects 
in severe symptomatic heart failure (HF), but data specifically in patients (Pts) with NYHA 
class IV and reduced ejection fraction are lacking. Therapeutic options are limited in 
NYHA class IV Pts, so effects of digoxin in this subset are of interest. 
Methods: The DIG Study. a large-scale prospective trial of the effect of digoxin on mor- 
bidity and mortality, included Pts with NYHA class IV. Data from this trial were analyzed 
to assess the effect of digoxln in Pts with NYHA class IV HF and reduced ejection frac- 
tions. 
Results: A total of 142 Pts with NYHA class IV symptoms at baseline and LVEF (45% I” 
the DIG Study were analyzed. As a group, these patients had severe left ventricular dys- 
function (mean LVEF 24 r 9.1%) with 1 year and 3 year survival rates of 68% and 41% 
respectively. Of these Pts, 76 were randomized to digoxin and 66 to placebo. Unadjusted 
swvival analysis demonstrated a trend toward a lower mortality rate in Pts randomized to 
digoxin (hazard ratio 0.68 with 95% confidence interval of 0.45 - 1.03. p = 0.068). Multi- 
variate, Cox analysis adjusting for baseline characteristics predictive of survival in this 
subset (prior digoxin therapy, systolic blood pressure, ischemic etiology, diabetes, and 
HF score), indicated that digoxin therapy was associated with better survival (hazard 
ratio 0.47 with 95% confidence intewal of 0.30 - 0.74, p = 0.001). Similar adjusted analy- 
sis found digoxin reduced the risk of the combined endpoint of mortality and time to first 
hospitalization for HF (hazard ratio 0.51 with 95% confidence interval 0.34 0.76, p = 
0.001). 
Conclusions. Retrospective analysis of the DIG Study results suggests digoxin is effica- 
1085-82 Sildenafil (Viagrafi) Improves Arterial Stiffness and 
Reduces Left Ventricular Load in Patients With 
Congestive Heart Failure 
Kozo Hirata, Charalambos Vlachopoulos, Audrey Adji, Michael F. O’Rourke, St. 
Vincent’s Clinic, University of New South Wales, Sydney, Australia 
Background: Sildenafil (S) is an effective drug for erectile dysfunction affecting the nitric 
oxide-cGMP pathway. The impairment of this pathway has been implicated in the patho- 
genesis of congestive heart failure (CHF). Arterial Stiffness and wave reflectlon are 
important determinants of left ventricular function, while wave reflection has also been 
inversely associated with exercise capacity. 
Methods: To investigate the effect of S on arterial stiffness and wave reflection in CHF 
we studied 20 patients (age 48-88 yrs) in NYHA class II or III (EF<35%), in a randomized. 
double-blind, placebo-controlled, cross-over design (50 mg of S and placebo). Carotid- 
femoral (aortic) and leg pulse wave velocity (PWV) ware measured as indices of arterial 
stiffness using a validated device (Complio@). Wave reflection was studied by maasur- 
ing augmentation index (Alx) using a validated system (SphygmoCorB) that employs 
high-fidelity arterial tonomeby and pulse wave analysis. 
Results: S was well tolerated with no side affects in any patient. S caused a decrease in 
left ventricular systolic pressure and on aortic pulse pressure by 13.9 mmHg and 4.8 
mmHg respectively (net sildenafil minus placebo effect, graph). Aorlic and leg PWV and 
Alx were also decreased by 0.89 m/set, 1.14 m/set, and 3.5% (graph). 
Conclusions: S leads to an improvement in arterial stiffness and to a reduction in left 
ventricular load in patients with CHF. This has important implications for cardiac perfor- 
mance and exercise capacity in such patients. 
1085-83 Serum Digoxin Concentration and the Efficacy of 
Digoxin Therapy in the Treatment of Heart Failure 
Saif S. Rathore, Jeptha P. Curtis, Yongfei Wang, Harlan M. Krumholz, Yale University 
School of Medicine, New Haven, CT 
Background: The association of serum digoxin (DIG) concentrations and all-cause mor- 
tality in patients with stable heart failure has not been assessed. 
Methods: We conducted an analysis of the Digitalis Investigation Group trial to assess 
variations in serum DIG concentration and their association with mortality. Because of a 
sex’DIG therapy interaction and the small number of women with measured serum DIG 
levels, analysis was restricted to male patients with an ejection fraction g5% (n=3,782). 
Patients randomized to DIG were divided into three groups based on their serum DIG 
concentration (SDC, in ng/mL) at 1 month - SDC a.8 (n=572), SDC 0.9 to 1 .l (n=322). 
and SDC _>I .2 (n=277) - and compared with patients randomized to placebo (n=2,811). 
Multivariable Cox proportional hazards analysis adjusting for age, renal function, LVEF, 
NYHA class, other patient characteristics, and medical therapy was conducted to assess 
the assoclabon of SDC and all-cause mortality (mean follow-up: 37 months). 
Results: Mortality rates were similar for patients randomized to placebo and DIG (36.2% 
vs. 36.6%. P=O.80). However, higher SDCs were associated with increased crude mor- 
tallty rates (SDC a.8 29.9%; SDC 0.9 to 1 .I 38.8%; SDC 21.2 48.0%, P<O.OOl for 
trend). Patients with SDC a.8 had a 6.3% (95% Cl 2.1%, 10.5%) lower all-cause mortal- 
ity rate than patients randomized to placebo. DIG was not associated with a reduction in 
all-cause mortality rates among patients with SDC 0.9 to 1.1 (2.6%. 95% Cl -3.O%, 
8.3%), while patients with SDC 21.2 had an 11.8% (95% Cl 5.7%, 18.0%) higher abso- 
lute mortality rate than patients randomized to placebo. After multivariable adjustment, 
all-cause mortality risks ware lower among patients with SDC a.8 (hazard ratio (HR] 
0.80, 95% Cl 0.68, 0.94), statistically comparable among patients with SDC 0.9 to 1 .I 
(HR 0.89. 95% Cl 0.74, 1.06), and trended toward increased harm among patients with 
SDC 21.2 (HR 1.16.95% Cl 0.96, 1.39) compared with patients randomized to placebo. 
Conclusions: Our findings suggest that the efficacy of digoxin therapy is optimized in 
the serum DIG concentration range of 0.5 ng/mL to 0.8 ng/mL among stable male hearl 
failure patients with left ventricular dysfunctidn. 
